Mifepristone for uterine fibroids

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 1, 2012, Pages

  Tristan, Mario ^a   Orozco, Leonardo J ^b   Steed, Antonia ^c   Ramirez Morera, Anggie ^b   Stone, Peter ^c  

^a Intl Health Central American Inst   (Costa Rica)

^b CAJA COSTARRICENSE DE SEGURO SOCIAL   (Costa Rica)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; PROGESTERONE RECEPTOR;

DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; LEIOMYOMA; MENORRHAGIA; META ANALYSIS; PATHOLOGY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR VOLUME; UTERUS CANCER;

FEMALE; HUMANS; LEIOMYOMA; MENORRHAGIA; MIFEPRISTONE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PROGESTERONE; TUMOR BURDEN; UTERINE NEOPLASMS;

EID: 84866759293     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007687.pub2     Document Type: Review

References (45)

1. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. The Australian & New Zealand Journal of Obstetrics & Gynaecology 2009;49(1):77-83. x-wiley/crsRef/16271160 [PMID: 19281585]
2. Engman M, Granberg S, Williams A, Meng C, Lalitkumar P, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Human Reproduction 2009;24(8):1870-9. x-wiley/crsRef/16271162
3. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomised controlled trial. Obstetrics & Gynecology 2006;108:1381-7. x-wiley/crsRef/16271164 [PMID: 17138770]
4. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas. Obstetrics & Gynecology 2008;112:1029-36. x-wiley/crsRef/16271166 [PMID: 18978102]
5. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstetrics & Gynecology 2003;101(2):243-50. x-wiley/crsRef/16271168 [PMID: 12576246]
6. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. Journal Minimally Invasive Gynecology 2005;12(3):227-33. x-wiley/crsRef/16271170 [PMID: 15922980]
7. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomised study. American Journal Obstetrics and Gynecology 1994;170(6):1623-7. x-wiley/crsRef/16271172 [PMID: 8203418]
8. Yang Y, Zheng S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Chinese Journal Obstetrics and Gynecology 1996;31(10):624-6. x-wiley/crsRef/16271174 [PMID: 9275461]
9. Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone. Zhonghua fu chan ke za zhi 1998;33(8):490-2. x-wiley/crsRef/16271176
10. Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
11. Drinville SJ, Memarzadeh S. Bengn disorders of the uterine corpus. In: DeCherney AH, editors(s). Current Diagnosis & Treatment Obstetrics & Gynecology. 10 edition. New York: McGraw-Hill, 2007:639-53.
12. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
13. Egger MDG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
14. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstetrics & Gynecology 2002;99(2):229-34.
15. Garzo VG, Liu J, Ulmann A, Baulieu, Yen SSC. Effects of an antiprogesterone (RU-486) on the hypothalamic-hypophysealovarian-endometrial axis during the luteal phase of the menstrual cycle. The Journal of Clinical Endocrinology and Metabolism 1988;66:508-16.
16. GRADE Working Group GRADE Profile Software. GRADE Working Group. GRADE Working Group, 2011.
17. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clinical Obstetrics & Gynecology 2001;44:385-400.
18. Hart R, Khalaf Y, Yeong CT, Seed P, Taylor A, Braude P. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Human Reproduction 2001;16:2411-7.
19. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Hopewell S, Clarke MJ, Lefebvre C, Scherer RW. Handsearching versus electronic searching to identify reports of randomised trials. Cochrane Database of Systematic Reviews 2007, Issue 2.
21. Hopewell S, McDonald S, Clarke MJ, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database of Systematic Reviews 2007, Issue 2.
22. Istre O. Conservative treatment of fibroids. Gynecological Surgery 2007;4(2):73-8.
23. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. American Journal of Obstetrics and Gynecology 1989;160:637-41.
24. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SSC. Endocrine responses to long-term administration of the antiprogesterone RU-486 in patients with pelvic endometriosis. Fertility and Sterility 1991;56:402-7.
25. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Molecular and Cellular Endocrinology 2012;358:223–31.
26. Lethaby A, Vollenhoven B. Fibroids. Clinical Evidence 2002;14:1666-78.
27. Liu JH, Garzo VG, Morris S, Stuenkel C, Ulmann A, Yen SSC. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. Journal of Clinical Endocrinology and Metabolism 1987;65:1135-140.
28. Liu JP, Yang H, Xia Y, Cardini F Liu JP, Yang H, et al. Herbal preparations for uterine fibroids. Cochrane Database of Systematic Reviews 2009, Issue 2.
29. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstetrics & Gynecology 1997;90:967-73.
30. Meniru GI, Wasdahl D, Onuora CO, Hecht BR, Hopkins MP. Vaginal leiomyoma co-existing with broad ligament and multiple uterine leiomyomas. Archives of Gynaecology & Obstetrics 2001;265:105-7.
31. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertility and Sterility 1995;64:187-90.
32. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology 2008;21(5):591-8.
33. Myers E, Barber M, Gustilo-Ashby T, Couchman G, Matchar D, Macrory D. Management of uterine leiomyomata: what do we really know? Obstetrics & Gynecology 2002;100:8-17.
34. Narvekar N, Cameron S, Critchley HOD, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. Journal of Clinical Endocrinology and Metabolism 2004;89(5):2491-7.
35. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. American Journal of Obstetrics and Gynecology 1995;172:14-8.
36. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2001.
37. Roseff SR, Kettel LM, Rivier J, Burger HG, Baulieu EE, Yen SSC. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women. Fertility and Sterility 1990;54:805-10.
38. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. International Journal of Epidemiology 2002;31(1):88-95.
39. Spies JB, Coyne K, Guaou NG, Boyle D, Skyrnarz-Murphy K, Gonzalves S. The UFS-QOL, a New Disease-Specific Symptom and Health-Related Quality of Life Questionnaire for Leiomyomata. Obstetrics & Gynecology 2002;99:290–300.
40. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstetrics & Gynecology 2004;103:1331-6.
41. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. British Medical Journal 1998;316(7129):469-70.
42. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 1985;4:89-96.
43. Vikhliaeva EM, Uvarova EV, Samedova N. The mechanism of the therapeutic effect of norethisterone in hyperplastic diseases of the endo- and myometrium in women of reproductive age [in Russian]. Voprosy Onkologii 1990;36:683-9.
44. Wallach E, Vlahos FN. Uterine myomas: an overview of development, clinical features, and management. Obstetrics & Gynecology 2004;104:393-406.
45. West CP. GnRH analogues in the treatment of fibroids. Reproductive Medicine Review 1993;2:1-97.